The end of anti-kickback protection from drug rebating would be bearish for PBMs and other middlemen in the US drug-supply chain, IMO. For drug/biotech companies, I would expect such a policy change to generate some short-term disruption but no lasting damage.
Market Data 
Markets 
AI
